Sandoz Enters Agreement with Polpharma Biologics to Develop and Commercialize Tysabri Biosimilar
Sandoz, a division of Novartis dedicated to the development of biosimilars, has entered an agreement with Polpharma Biologics, a biopharmaceutical company also dedicated to the manufacture of biosimilars, to develop and market a biosimilar to Biogen‘sĀ Tysabri (natalizumab). Tysabri is a disease-modifying therapy (DMT) that wasĀ …